Drug intelligence / Profile preview

T3P-Y008

Development stage: Preclinical
Lead developer: Boehringer Ingelheim
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous

Overview

T3P-Y008 is an experimental microbial immunotherapy being developed by T3 Pharmaceuticals, a subsidiary of Boehringer Ingelheim. It is part of a series of candidates based on the company's proprietary T3 Protein Delivery Platform, which utilizes engineered, attenuated *Yersinia enterocolitica* bacteria to deliver therapeutic proteins directly into solid tumors. The bacteria are designed to selectively colonize the tumor microenvironment, particularly hypoxic and necrotic regions, and use a natural Type 3 Secretion System (T3SS) to inject functional protein cargoes directly into the cytoplasm of tumor cells or the surrounding milieu. This localized delivery approach is intended to provide high therapeutic concentrations of agents such as cytokines or immune modulators while minimizing systemic exposure and associated toxicities. T3P-Y008 is currently in the preclinical stage of development for the treatment of various solid tumors, following the lead clinical candidate T3P-Y058-739.

Beyond the preview

Go deeper on T3P-Y008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T3P-Y008.

Explore the full profile